Novartis AG
COMBINATION TREATMENT OF LIVER DISEASES USING FXR AGONISTS

Abstract:

The present invention relates to combinations for treating, preventing, or ameliorating conditions mediated by farnesoid X receptors (FXRs), in particular liver diseases or intestinal disease, comprising administering to a subject in need thereof a therapeutically effective amount of an FXR agonist.